Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1978 Jan;75(1):464–467. doi: 10.1073/pnas.75.1.464

[18F]Fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine

E S Garnett 1,*, G Firnau 1, P K H Chan 1, S Sood 1, L W Belbeck 1
PMCID: PMC411270  PMID: 415309

Abstract

3,4-Dihydroxy-5-fluorophenylalanine, fluorodopa, was injected into rats in which unilateral lesions of the nigrostriatal pathway had been made. The rats rotated towards the side with the lesions, thus providing further evidence that fluoro-dopa is an analogue of dopa. [18F]Fluoro-dopa was then injected intravenously into fully conscious baboons. A well-collimated scintillation detector, aligned along the occipitomental axis, recorded the accumulation of 18F in the brain. Control animals accumulated 18F continuously for 100 min. This accumulation represents net transport of [18F]fluoro-dopa from blood to brain, decarboxylation to [18F]fluoro-dopamine, storage, and degradation of [18F]fluoro-dopamine. α-Methyl-dopa, a competitive inhibitor of dopa transport and decarboxylation, prevented the accumulation of 18F; reserpine, known to release stored intracerebral dopamine, discharged 18F; pargyline, a monoamine oxidase inhibitor, and haloperidol, a known augmentor of intracerebral dopamine turnover, increased the rate of accumulation of 18F. These changes in the accumulation of intracerebral 18F, after [18F]fluoro-dopa, were commensurate with the known action of the drugs used to induce them and demonstrate the use of a γ-emitting precursor of a neurotransmitter to monitor simply, atraumatically, and externally the intracerebral metabolism of the transmitter in fully conscious primates. When applied to man, the same technique should be able to provide more conclusive evidence than is presently available for the role of catecholamines in schizophrenia and depression. It should also provide further insight into the natural history of nigrostriatal diseases and the action of drugs used in their treatment.

Keywords: Parkinson disease, schizophrenia

Full text

PDF
464

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartholini G., Kuruma I., Pletscher A. Distribution and metabolism of L-3-O-methyldopa in rats. Br J Pharmacol. 1970 Nov;40(3):461–467. doi: 10.1111/j.1476-5381.1970.tb10627.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carlsson A. Modification of sympathetic function. Pharmacological depletion of catecholamine stores. Pharmacol Rev. 1966 Mar;18(1):541–549. [PubMed] [Google Scholar]
  3. Firnau G., Garnett E. S., Chan P. K., Belbeck L. W. Intracerebral dopamine metabolism studied by a novel radioisotope technique. J Pharm Pharmacol. 1976 Jul;28(7):584–585. doi: 10.1111/j.2042-7158.1976.tb02801.x. [DOI] [PubMed] [Google Scholar]
  4. Firnau G., Garnett E. S., Sourkes T. L., Missala K. (18F) Fluoro-Dopa: a unique gamma emitting substrate for Dopa decarboxylase. Experientia. 1975 Nov 15;31(11):1254–1255. doi: 10.1007/BF01945762. [DOI] [PubMed] [Google Scholar]
  5. Firnau G., Nahmias C., Garnett S. The preparation of ( 18 F)5-fluoro-DOPA with reactor-produced fluorine-18. Int J Appl Radiat Isot. 1973 Mar;24(3):182–184. doi: 10.1016/0020-708x(73)90008-2. [DOI] [PubMed] [Google Scholar]
  6. Kirk K. L. Photochemistry of diazonium salts. 4. Synthesis of ring-fluorinated tyramines and dopamines. J Org Chem. 1976 Jul 9;41(14):2373–2376. doi: 10.1021/jo00876a004. [DOI] [PubMed] [Google Scholar]
  7. Langelier P., Parent A., Poirier L. J. [Decarboxylase activity of the brain capillary walls and parenchyma in the rat, cat and monkey]. Brain Res. 1972 Oct 27;45(2):622–629. doi: 10.1016/0006-8993(72)90495-7. [DOI] [PubMed] [Google Scholar]
  8. Martin R. B. Zwitterion formation upon deprotonation in L-3, 4-dihydroxyphenylalanine and other phenolic amines. J Phys Chem. 1971 Aug 19;75(18):2657–2661. doi: 10.1021/j100686a021. [DOI] [PubMed] [Google Scholar]
  9. Pardridge W. M., Oldendorf W. H. Transport of metabolic substrates through the blood-brain barrier. J Neurochem. 1977 Jan;28(1):5–12. doi: 10.1111/j.1471-4159.1977.tb07702.x. [DOI] [PubMed] [Google Scholar]
  10. Raichle M. E., Larson K. B., Phelps M. E., Grubb R. L., Jr, welch M. J., Ter-Pogossian M. M. In vivo measurement of brain glucose transport and metabolism employing glucose- -11C. Am J Physiol. 1975 Jun;228(6):1936–1948. doi: 10.1152/ajplegacy.1975.228.6.1936. [DOI] [PubMed] [Google Scholar]
  11. SOURKES T. L., MURPHY G. F., CHAVEZ B., ZIELINSKA M. The action of some alpha-methyl and other amino acids on cerebral catecholamines. J Neurochem. 1961 Nov;8:109–115. doi: 10.1111/j.1471-4159.1961.tb13532.x. [DOI] [PubMed] [Google Scholar]
  12. Shindo H., Nakajima E., Kawai K., Miyakoshi N., Tanaka K. Studies on the metabolism of D- and L-isomers of 3,4-dihydroxyphenylalanine (DOPA). 3. Absorption, distribution and excretion of D- and L-DOPA-14C in rats following intravenous and oral administration. Chem Pharm Bull (Tokyo) 1973 Apr;21(4):817–825. doi: 10.1248/cpb.21.817. [DOI] [PubMed] [Google Scholar]
  13. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971;367:69–93. doi: 10.1111/j.1365-201x.1971.tb11000.x. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES